Disease · MONDO_0002911
brain stem glioma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. brain stem glioma. Diseases, record MONDO_0002911. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002911
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
brain stem neuroglial neoplasm, brain stem neuroglial tumor, brain stem neuroglial tumour, brainstem glioma, brainstem malignant glioma, brainstem neuroglial neoplasm, brainstem neuroglial tumor, brainstem neuroglial tumour, diffuse brainstem glioma, glioma of brain stem, glioma of brainstem, glioma of the brain stem, glioma of the brainstem, malignant glioma of brainstem
- Open Targets
Drugs27
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ANTINEOPLASTON A10 | CHEMBL1980825 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PHENYLACETIC ACID | CHEMBL1044 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LABRADIMIL | CHEMBL2105864 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TIPIFARNIB | CHEMBL289228 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CATEQUENTINIB | CHEMBL4303201 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TAMOXIFEN | CHEMBL83 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 27
See all 27 drugsTargets100
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 3 | Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ESR1 | Estrogen receptor | 2 | Estrogen receptor alpha modulator | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 2 | Platelet-derived growth factor receptor beta inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 2 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 2 | Tubulin inhibitor | Phase 1 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 2 | Tubulin inhibitor | Phase 1 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 2 | Tubulin inhibitor | Phase 1 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 100
See all 100 targetsTrials24
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00021229 | Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma | Phase 1/2 | 85 | 2010-04-09 | Brain and Central Nervous System Tumors | IMATINIB MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | Phase 1/2 | 69 | 2011-07-11 | Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma | GEFITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00079339 | Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma | Phase 1/2 | 51 | 2010-09-24 | Untreated Childhood Brain Stem Glioma | TIPIFARNIB | Its record names the disease | ClinicalTrials.gov |
| NCT00108069 | Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors | Phase 2 | 43 | 2014-06-12 | Glioma | BORTEZOMIB, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT00532948 | A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas | Phase 1 | 24 | 2016-03-15 | Glioma | CAPECITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00070525 | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma | Phase 2 | 90 | Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma | TIPIFARNIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03932981 | First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression | Phase 2 | 60 | Adult Brainstem Glioma | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00004068 | Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor | Phase 2 | 53 | Brain and Central Nervous System Tumors | IRINOTECAN, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00360854 | Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma | Phase 1 | 48 | Brain and Central Nervous System Tumors | ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00418327 | Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma | Phase 1 | 48 | Malignant Brain Tumor, Brain Stem Glioma, | ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| GBM (Glioblastoma Multiforme) vs AG (Anaplastic Glioma): Number of Participants With Adverse Events | 30 of 30 | 12 of 12 | 42 | NCT00108069 | Trial comparisons |
| GBM (Glioblastoma Multiforme) vs AG (Anaplastic Glioma): serious adverse events | 11 of 30 | 3 of 12 | 42 | NCT00108069 | Trial comparisons |
Stratum IIA: Imatinib Mesylate vs Stratum IIB: Imatinib Mesylate: Number of Participants in Phase I Stratum II With Dose Limiting Toxicities (DLT) Observed During First 8 Weeks (Courses 1 and 2) of Imatinib Therapy | 2 of 20 | 0 of 12 | 32 | NCT00021229 | Trial comparisons |
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002911
GET https://conductscience.org/api/diseases/v1/MONDO_0002911/drugs?page=2